Seagen Inc. (NASDAQ: SGEN) will report its Q3 2022 financial results on October 27, 2022, after U.S. market close. A conference call and webcast will follow at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Investors can access the conference by calling 844-763-8274 (U.S.) or +1 412-717-9224 (international) with conference ID 10171976. Seagen, headquartered in Seattle, develops transformative cancer medicines.
Positive
None.
Negative
None.
Insights
Analyzing...
BOTHELL, Wash.--(BUSINESS WIRE)--
Seagen Inc. (Nasdaq: SGEN) today announced that it will report its third quarter 2022 financial results on Thursday, October 27, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.
Conference call and webcast information:
Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 10171976
Webcast with slides can be accessed at investor.seagen.com. A webcast replay will be archived on the Company’s website.
About Seagen
Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.